Zymeworks Inc. is a Vancouver-based clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. Utilizing its proprietary platforms, Zymeworks has built a robust pipeline featuring antibody-drug conjugates and bispecific therapeutics, designed to meet significant unmet medical needs in oncology. The company's commitment to advancing targeted therapies, combined with strategic collaborations, positions it as a key contributor to the evolving biopharmaceutical sector, with the potential to deliver transformative solutions for patients suffering from various types of cancer. Show more

Location: 108 PATRIOT DRIVE, MIDDLETOWN, DE, UNITED STATES, 19709, Middletown, DE, 19709, USA | Website: https://www.zymeworks.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE


Market Cap

1.716B

52 Wk Range

$9.03 - $28.49

Previous Close

$22.53

Open

$22.45

Volume

455,482

Day Range

$22.45 - $23.34

Enterprise Value

1.453B

Cash

64.83M

Avg Qtr Burn

-31.41M

Insider Ownership

0.98%

Institutional Own.

-

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ziihera® (zanidatamab-hrii) Details
Cancer, Solid tumor/s, Biliary Tract Cancer

Approved

Quarterly sales

Zanidatamab + Chemo/trastuzumab Details
Breast cancer, Cancer, HER2-expressing cancers

Approved

Quarterly sales

Zanidatamab (HER2) + chemotherapy + tislelizumab Details
Cancer, Gastroesophageal adenocarcinomas, Cholangiocarcinoma

Phase 3

Data readout

Phase 3

Initiation

Zanidatamab zovodotin (ZW49) Details
HER2-expressing cancers, Cancer, Non-small cell lung carcinoma

Phase 2

Update

Phase 1/2

Update

ZW171 Details
Mesothelin-expressing solid tumors

Phase 1

Update

ZW191 Details
Cancer, Solid tumor/s

Phase 1

Update

ZW251 (GPC3 ADC) Details
Hepatocellular carcinoma (HCC)

Phase 1

Update

IND

Submission

ZW418 (PTK7 ADC) Details
Cancer, Solid tumor/s

IND

Submission

IND

Submission